GraniteShares YieldBOOST CRCL 

$22.26
17
+$0.79+3.66% 今天

統計

當日最高
22.29
當日最低
22.2
52週高點
25.93
52週低點
21.48
成交量
54,662
平均成交量
-
市值
874.96M
本益比
-
股息殖利率
94.4%
股息
21.01

即將到來

股息

94.4%股息殖利率
Jul 26
$0.40
Jul 26
$0.40
Jun 26
$0.40
Jun 26
$0.40
Jun 26
$0.40
10年成長
不適用
5年成長
不適用
3年成長
不適用
1年成長
不適用

財報

9Feb預期
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
-0.18
-0.03
0.11
0.26
預期EPS
-0.1
實際EPS
不適用

其他人也在關注

此清單是根據在 Stock Events 上追蹤 CRY 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Artivion Inc., established in 1984 and based in Kennesaw, Georgia, functions globally as a manufacturer, processor, and distributor of both medical devices and implantable human tissues. Previously known as CryoLife, Inc., the company underwent a rebranding to Artivion Inc. in January 2022. Artivion caters to a wide array of clients, including physicians, hospitals, various healthcare facilities, and specialized surgeons in cardiac, vascular, thoracic, and general fields. Their comprehensive product portfolio features BioGlue, a polymer formulated from bovine blood protein for use in cardiac, vascular, pulmonary, and general surgical procedures. They also provide the On-X line of prosthetic aortic and mitral heart valves, alongside the On-X ascending aortic prosthesis. Artivion extends its services to include cardiac preservation and offers PhotoFix, a bovine pericardial patch, as well as the E-vita OPEN PLUS and E-vita OPEN NEO hybrid stent graft systems. The company is a prominent supplier of specialized stent grafts designed for numerous aortic and arterial conditions. These include the E-xtra DESIGN ENGINEERING products for aortic vascular diseases, E-nside as an off-the-shelf option for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular treatment of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, E-ventus BX for renal and pelvic arteries, E-liac for aneurysmal iliac arteries and their side branches, and E-tegra for abdominal aortic aneurysms. Further offerings encompass synthetic vascular grafts for open aortic and peripheral surgeries, PerClot (an absorbable powdered hemostat), and cardiac laser therapy equipment such as the SolarGen 2100s Console. They also provide CryoVein and CryoArtery vascular preservation services, CarbonAid CO2 diffusion catheters, Chord-X ePTFE sutures for mitral chordal replacement, and ascyrus medical dissection stents. Additionally, Artivion provides pyrolytic carbon coating services to other manufacturers in the medical device industry.
Show more...
執行長
員工
1200
國家
美國
ISIN
US38747T6661

上市

0 Comments

分享你的想法

FAQ

GraniteShares YieldBOOST CRCL 今天的股價是多少?
CRY 目前價格為 $22.26 USD,過去 24 小時上漲了 +3.66%。在圖表上更密切關注 GraniteShares YieldBOOST CRCL 股價表現。
GraniteShares YieldBOOST CRCL 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,GraniteShares YieldBOOST CRCL 的股票以代號 CRY 進行交易。
GraniteShares YieldBOOST CRCL 的市值是多少?
今天 GraniteShares YieldBOOST CRCL 的市值為 874.96M
GraniteShares YieldBOOST CRCL 會發放股息嗎?
是的,CRY 的股息每 每週 發放一次。每股最新股息為 0.4 USD。截至今日,股息殖利率(FWD)% 為 94.4%。
GraniteShares YieldBOOST CRCL 有多少名員工?
截至 June 15, 2026,公司共有 1,200 名員工。
GraniteShares YieldBOOST CRCL 位於哪個產業?
GraniteShares YieldBOOST CRCL從事於Other產業。
GraniteShares YieldBOOST CRCL 何時完成拆股?
GraniteShares YieldBOOST CRCL 最近沒有進行任何拆股。